HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia

HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia

As one of the most common malignancies worldwide, Hepatocellular carcinoma (HCC) has been treated by Sorafenib, which is the first approved target drug by FDA for advanced HCC. However, drug resistance is one of the obstacles to its application. As a typical characteristic of most solid tumors, hypo...

Full description

Bibliographic Details
Main Authors: Yan Liao, Yue Yang, Di Pan, Youxiang Ding, Heng Zhang, Yuting Ye, Jia Li, Li Zhao
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cancers
Subjects:
hepatocellular carcinoma
necroptosis
hypoxia
HSP90α
sorafenib resistance
Online Access:https://www.mdpi.com/2072-6694/13/2/243

Similar Items

Similar Items